Key result
Plasma adiponectin levels strongly correlated with insulin sensitivity in obese subjects (R2=0.36, p<0.0001) but not in lean subjects, indicating its role depends on body fat.
Why the study?
Does the association between plasma adiponectin and insulin sensitivity depend on the degree of obesity in normal glucose-tolerant subjects?
Observational (n=900)
Does the association between plasma adiponectin and insulin sensitivity depend on the degree of obesity in normal glucose-tolerant subjects?
Effect estimate: R2 = 0.36 (OGTT) and R2 = 0.48 (clamp) in upper body fat quartile
p-value: p=<0.0001
Adiponectin is especially critical in sustaining insulin sensitivity in obese subjects, suggesting that interventions to increase adiponectin may be most effective in obese, insulin-resistant individuals.
Supports adiponectin research in obese insulin-resistant patients; should not yet change practice based on observational data.
OBJECTIVE: In humans, low plasma adiponectin concentrations precede a decrease in insulin sensitivity and predict type 2 diabetes independently of obesity. However, it is possible that the contribution of adiponectin to insulin sensitivity is not equally strong over the whole range of obesity. RESEARCH METHODS AND PROCEDURES: We investigated the cross-sectional association between plasma adiponectin levels and insulin sensitivity in different ranges of body fat content [expressed as percentage of body fat (PFAT)] in a large cohort of normal glucose-tolerant subjects (n = 900). All individuals underwent an oral glucose tolerance test (OGTT), and 299 subjects additionally a euglycemic hyperinsulinemic clamp. In longitudinal analyses, the association of adiponectin at baseline with change in insulin sensitivity was investigated in a subgroup of 108 subjects. RESULTS: In cross-sectional analyses, the association between plasma adiponectin and insulin sensitivity, adjusted for age, gender, and PFAT, depended on whether subjects were lean or obese [p for interaction adiponectin x PFAT = <0.001 (OGTT) and 0.002 (clamp)]. Stratified by quartiles of PFAT, adiponectin did not correlate significantly with insulin sensitivity in subjects in the lowest PFAT quartile (R2 = 0.10, p = 0.13, OGTT; and R2 = 0.10, p = 0.57, clamp), whereas the association in the upper PFAT quartile was rather strong (R2 = 0.36, p < 0.0001, OGTT; and R2 = 0.48, p = 0.003, clamp). In longitudinal analyses, plasma adiponectin at baseline preceded change in insulin sensitivity in obese (n = 54, p = 0.03) but not in lean (n = 54, p = 0.68) individuals. DISCUSSION: These data suggest that adiponectin is especially critical in sustaining insulin sensitivity in obese subjects. Thus, interventions to reduce insulin resistance by increasing adiponectin concentrations may be effective particularly in obese, insulin-resistant individuals.
No takes yet. Share an insight, caveat, or question.
Kantartzis et al. (2005) conducted an observational in Normal glucose tolerance (n=900). Plasma adiponectin vs. Lean vs obese subjects (based on percentage of body fat) was evaluated on Insulin sensitivity (measured by OGTT and euglycemic hyperinsulinemic clamp) (R2 = 0.36 (OGTT) and R2 = 0.48 (clamp) in upper body fat quartile, p=<0.0001). Plasma adiponectin levels strongly correlated with insulin sensitivity in obese subjects (R2=0.36, p<0.0001) but not in lean subjects, indicating its role depends on body fat.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: